接受标准治疗的系统性血管炎患者对肺炎球菌结合疫苗的免疫应答
49例原发性系统性血管炎患者与49名健康对照各肌内注射单剂0.5ml PCV13,接种前及接种后4-6周检测6B和23F血清型特异性抗体及23F的OPA。两组接种后抗体均升高(p<0.001),患者接种后抗体水平呈低于对照的趋势;AZA、CYC或MTX治疗者达到保护性抗体的比例呈低于对照的趋势(p=0.06)。作者认为PCV13在已确诊血管炎患者中安全且有免疫原性。
要点
- 49例血管炎患者与49名对照接种单剂0.5ml PCV13,接种后两组6B和23F抗体均升高(p<0.001)。
- 接种后32例患者(65%)和35名对照(71%)6B达保护水平,23F为32例(65%)对37名(76%)。
- AZA、CYC或MTX治疗者达保护性抗体比例呈低于对照趋势(p=0.06),单用泼尼松龙未见此趋势。
核心结论
- 肺炎球菌结合疫苗在已确诊血管炎患者中安全且有免疫原性,DMARDs(主要为AZA、CYC和MTX)而非全身性泼尼松龙可能损害抗体应答。
研究设计与样本
- 研究纳入49例原发性系统性血管炎患者和49名健康对照,各肌内注射单剂0.5ml PCV13。
- 患者正在使用的治疗包括硫唑嘌呤(AZA;n=11)、环磷酰胺(CYC;n=6)、甲氨蝶呤(MTX;n=9)、利妥昔单抗(n=3)、抗TNF(n=2)、吗替麦考酚酯(n=2)、单用泼尼松龙(n=15)及无活跃治疗(n=2)。
- 于接种前和接种后4-6周采集血清,用ELISA测定6B和23F血清型特异性抗体浓度,并进行23F的调理吞噬活性(OPA)试验。
主要发现
- 基线时6例患者(12%)和12名对照(24%)两个血清型均具有保护性抗体水平。
- 接种后患者和对照两个血清型抗体均升高(p<0.001);6B达保护水平者为32例患者(65%)和35名对照(71%),23F为32例患者(65%)和37名对照(76%)。
- 与对照相比,患者接种前23F几何平均浓度较低(p=0.01),接种前6B水平及接种后两血清型水平呈数值上较低的趋势。
- 单用泼尼松龙的患者接种前OPA低于对照(p<0.01);接种后两组OPA均升高(p<0.001),但对照改善更佳(p=0.001)。
- AZA、CYC或MTX治疗者达到保护性抗体水平的比例呈低于对照的趋势(p=0.06),单用泼尼松龙者未见此趋势。
关键数值与推荐
- 保护性抗体浓度定义为≥1.0µg/mL,阳性抗体应答定义为较接种前浓度≥2倍升高。
临床怎么用
- 作者认为肺炎球菌结合疫苗在已确诊血管炎患者中安全且有免疫原性。
- 作者认为DMARDs(主要为AZA、CYC和MTX)而非全身性泼尼松龙可能损害抗体应答。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: To study the effect of standard of care therapy on antibody response and functionality following immunization with 13-valent pneumococcal conjugate vaccine (PCV13) in patients with primary systemic vasculitis compared to healthy controls. METHODS: 49 patients with vasculitis and 49 controls received a single dose (0.5ml) PCV13 intramuscularly. Ongoing treatments: azathioprine (AZA; n=11), cyclophosphamide (CYC; n=6), methotrexate (MTX; n=9), rituximab (n=3); anti-TNF (n=2), mycophenolate mofetil (n=2), prednisolone alone (n=15) and no active treatment (n=2). Specific antibody concentrations for serotypes 6B and 23F were determined using ELISA and opsonophagocytic activity (OPA) assay (23F) was performed, on serum samples taken immediately before and 4-6weeks after vaccination. Proportion of individuals with putative protective antibody concentration (≥1.0µg/mL) and positive antibody response (≥2-fold increase from prevaccination concentration) for both serotypes were calculated and groups were compared. RESULTS: At baseline, 6 patients (12%) and 12 controls (24%) had protective antibody levels for both serotypes. After vaccination, antibodies increased for both serotypes in patients and controls (p<0.001), 32 patients (65%) and 35 controls (71%) reached protective level for 6B, and 32 patients (65%) and 37 controls (76%) for 23F. Compared to controls, patients had lower prevaccination geometric mean concentration (23F, p=0.01) and a numerical trend towards lower prevaccination level (6B) and postvaccination levels (both serotypes). Patients with prednisolone alone had lower prevaccination OPA (p<0.01) compared to controls. OPA increased after vaccination in both patients and controls (p<0.001), but improvement was better in controls (p=0.001). AZA, CYC or MTX, but not prednisolone alone, tended towards a lower proportion of patients reaching protective antibody levels (p=0.06), compared to controls. CONCLUSIONS: Pneumococcal conjugate vaccine was safe and immunogenic in patients with established vasculitis. Treatment with DMARDs, mostly AZA, CYC and MTX but not systemic prednisolone may impair antibody response. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02240888. Registered 4 September, 2014.
引用
- Nived P, Nagel J, Saxne T, et al. Immune response to pneumococcal conjugate vaccine in patients with systemic vasculitis receiving standard of care therapy. Vaccine. 2017. PMID: 28552512. doi:10.1016/j.vaccine.2017.05.044
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。